《C&EN》1984年8月13日。纽约大学医学中心和国立卫生研究院的科学家们克服了生产人疟疾疫苗的最后障碍,克隆出疟原虫的主要表面抗原基因。两个研究组用的是不同的方法。现已能大量生产抗原并开始测试其安全性和疫苗的有效性。支持此项研究基金的国际开发组织负责人M Peter McPherson说,他预计这一疫苗在12—18个月内可以使用,全世界五年内可广泛使用。疟疾是最大的单因素疾病,全世界每年 C & EN August 13, 1984. Scientists at the New York University Medical Center and the National Institutes of Health have overcome the last hurdle of producing human malaria vaccine by cloning the major surface antigen genes of the malaria parasite. The two study groups used different methods. It is now possible to mass-produce antigens and start testing their safety and vaccine effectiveness. M Peter McPherson, head of the International Development Organization that supports the research fund, said he expects the vaccine to be available in 12-18 months and is widely available worldwide for five years. Malaria is the largest single factor disease worldwide every year